{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:55:37Z","timestamp":1790679337179,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study was conducted to review and synthesize current evidence on anti\u2010calcitonin gene\u2010related peptide (CGRP) therapies in women with menstrual\u2010related migraine, during pregnancy and lactation, and while using hormonal contraception.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Migraine disproportionately affects women, with prevalence peaking during reproductive years when hormonal fluctuations modulate neurovascular and nociceptive pathways, including CGRP signaling, that contribute to migraine susceptibility. Despite the established efficacy of anti\u2010CGRP therapies\u2014including monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) and gepants (ubrogepant, rimegepant, atogepant, and zavegepant)\u2014evidence regarding their use across critical reproductive health contexts remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of MEDLINE and Embase was conducted using MeSH terms and keywords related to migraine, CGRP\u2010targeted therapies, and reproductive health contexts. Studies were screened independently by two reviewers. Data were extracted using standardized forms and synthesized narratively by clinical domain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sixteen studies met inclusion criteria. For menstrual\u2010related migraine,\n                      <jats:italic>post hoc<\/jats:italic>\n                      analyses and observational studies demonstrate that CGRP monoclonal antibodies reduce migraine frequency both during and outside the perimenstrual window (galcanezumab: \u22125.1 vs. \u22123.2\u2009days,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), although the perimenstrual period remains a time of relatively higher headache burden despite treatment. Pregnancy data are limited to pharmacovigilance analyses and case reports of unintended exposures, which have not identified specific patterns of maternal, fetal, or neonatal toxicity. Phase 1 pharmacokinetic studies demonstrate minimal gepant transfer into breast milk (relative infant doses, 0.04%\u20130.19%), well below the 10% safety threshold, although no human lactation data exist for CGRP monoclonal antibodies. No studies specifically evaluated anti\u2010CGRP therapies in women using hormonal contraceptives.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Substantial evidence gaps exist across all reproductive health contexts examined. Prospective trials in menstrual\u2010related migraine, pregnancy registries, lactation studies assessing infant outcomes, and research examining interactions with hormonal contraceptives are needed to optimize migraine care for women.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.70195","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:59:13Z","timestamp":1790675953000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti\u2010calcitonin gene\u2010related peptide treatments in women's health: Gaps and clinical evidence in menstrual\u2010related migraine, pregnancy, lactation, and hormonal contraception: A narrative review"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9974-9208","authenticated-orcid":false,"given":"Jelena","family":"Pejic","sequence":"first","affiliation":[{"name":"Mayo Clinic Alix School of Medicine  Scottsdale Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeya","family":"Anandakumar","sequence":"additional","affiliation":[{"name":"Georgetown University School of Medicine  Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Marks","sequence":"additional","affiliation":[{"name":"Department of Library Services Mayo Clinic Arizona  Scottsdale Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4280-4440","authenticated-orcid":false,"given":"Rashmi B.","family":"Halker Singh","sequence":"additional","affiliation":[{"name":"Department of Neurology Mayo Clinic  Scottsdale Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ailani","sequence":"additional","affiliation":[{"name":"Department of Neurology Georgetown University  Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2020.1724285"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2019.06.001"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/17455057251376878"},{"key":"e_1_2_10_5_1","volume-title":"StatPearls","author":"Rashid A","year":"2026"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-050224-111631"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1607393"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000001372"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102416637833"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14652"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15794"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11030370"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251332519"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1089\/bfm.2021.0250"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1066"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00772-4"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.70036"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231158083"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01715-4"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14393"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241273966"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14305"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-01052"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-00551"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14692"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30482-8"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2194487"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01848-6"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14775"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"},{"issue":"5","key":"e_1_2_10_31_1","first-page":"443","article-title":"Migraine headache prophylaxis","volume":"111","author":"Moreland P","year":"2025","journal-title":"Am Fam Physician"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00477-6"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000003176"},{"key":"e_1_2_10_34_1","volume-title":"NURTEC ODT (rimegepant) [prescribing information]","author":"Food and Drug Administration","year":"2026"},{"key":"e_1_2_10_35_1","volume-title":"UBRELVY (ubrogepant) [prescribing information]","author":"Food and Drug Administration","year":"2025"},{"key":"e_1_2_10_36_1","unstructured":"Food and Drug Administration.QULIPTA (atogepant) [prescribing information].Allergan Inc.2025. Accessed May 3 2026.https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=8c8ab8f4\u201032bd\u2010497a\u2010befa\u201070c8a51d8d52"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.70195","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.70195","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.70195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:59:16Z","timestamp":1790675956000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.70195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":35,"alternative-id":["10.1111\/head.70195"],"URL":"https:\/\/doi.org\/10.1111\/head.70195","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"2026-05-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"head.70195"}}